论文部分内容阅读
目的:探讨支气管舒张剂联合抗胆碱药在慢性阻塞性肺疾病合并支扩的临床应用效果。方法:选取我院呼吸内科诊治的慢阻肺合并支扩患者84例作为研究对象,根据应用药物的不同分为A、B、C三组,A组雾化吸入布地奈德混悬液+硫酸特布他林雾化液;B组吸入用布地奈德混悬液+吸入用异丙托溴铵溶液;C组吸入用布地奈德混悬液+硫酸特布他林雾化液+吸入用异丙托溴铵溶液,评估治疗前后三组患者的肺功能变化,以及住院费用、住院时间情况并比较。结果:治疗结束后,三组患者FEV1、FEV1/FVC均较治疗前明显改善,有统计学意义(p<0.05);且C组患者肺功能改善幅度较A、B组更明显,差异有统计学意义;C组患者住院费用较A、B组高,差异显著,有统计学意义(p<0.05);住院时间,C组明显较A、B组缩短,差异有统计学意义(p<0.05)。结论:吸入用布地奈德混悬液联合硫酸特布他林与异丙托溴铵联合用药经氧气雾化吸入治疗慢阻肺合并支扩,能明显改善患者肺功能,缩短住院时间,减少费用。
Objective: To investigate the clinical effect of bronchodilator combined with anticholinergic drugs in the treatment of chronic obstructive pulmonary disease (COPD). Methods: Eighty-four patients with chronic obstructive pulmonary disease complicated with dilatation and debridement who were diagnosed and treated in our department were divided into A, B and C groups. Group A received budesonide suspension and sulfuric acid Terbutaline nebulized liquid; Group B budesonide suspension for inhalation + ibuprofen inhalation solution; Group C inhalation budesonide suspension + terbutaline sulphate aerosol + inhalation Ipratropium bromide solution before and after treatment to assess changes in lung function in three groups of patients, and hospitalization costs, length of stay and more. Results: At the end of treatment, the FEV1 and FEV1 / FVC in all three groups were significantly improved compared with those before treatment (p <0.05); and the improvement of pulmonary function in group C was more obvious than that in group A and B (P <0.05); hospitalization time, C group was significantly shorter than A, B group, the difference was statistically significant (p <0.05); hospitalization costs in group C were significantly higher than those in group A and B ). Conclusion: Inhalation of budesonide suspension combined with ipratropium sulfate and inhalation of oxygen inhalation for chronic obstructive pulmonary syndrome with inhalation of buprenorphine and ipratropium bromide can significantly improve lung function, shorten hospitalization time and reduce costs .